Диссертация (1173248), страница 15
Текст из файла (страница 15)
759–767.75.Hattingen, E. Myoinositol: a marker of reactive astrogliosis in glial tumors? /E. Hattingen, P. Raab, K. Franz et al. // NMR in Biomedicine. – 2008. – Vol. 21. –P. 233–241.10476.Hernandez-Alcoceba, R. Choline kinase inhibitors as a novel approach forantiproliferative drug design / R. Hernandez-Alcoceba, L. Saniger, J. Campos et al.// Oncogene. – 1997.
– Vol. 15. – P. 2289–2301.77.Hollingworth, W. Systematic Literature Review of Magnetic ResonanceSpectroscopy for the Characterization of Brain Tumors / W. Hollingworth, L. S.Medina, R. E. Lenkinski et al. // Am. J. Neuroradiol. - 2006. - Vol. 27. - P. 1404 –1411.78.Horska, A. Imaging of brain tumors: MR spectroscopy and metabolic imaging/ A. Horska, P. B. Barker // Neuroimaging Clinics of North America.
– 2010. – Vol.20. – P. 293–310.79.Houkin, K. Longitudinal changes in proton magnetic resonance spectroscopyin cerebral infarction / K. Houkin, K. Kamada, H. Kamiyama et al. // Stroke. – 1993.– Vol. 24. – P. 1316- 1321.80.Howe, F. A Metabolic profiles of human brain tumors using quantitative invivo 1H magnetic resonance spectroscopy / F. A.
Howe, S. J. Barton, S. A. Cudlipet al. // Magn Reson Med. – 2003. – Vol. 49(2). – P. 223–232.81.Howe, F. A. Metabolic profiles of human brain tumors using quantitative invivo 1H magnetic resonance spectroscopy / F. A. Howe, S. J. Barton, S. A. Cudlipet al. // Magnetic Resonance in Medicine: Official Journal of the Society of MagneticResonance in Medicine. – 2003. – Vol. 49. – P. 223–232.82.Huang, W.
Brain metabolite concentration and dementia severity inAlzheimer’s disease: a (1)H MRS study / W. Huang, G. E. Alexander, L. Chang etal. // Neurology. – 2001. – Vol. 57(4). – P. 626–632.83.Isaacks, R. E. Osmotic regulation of myo-inositol uptake in primary astrocytecultures / R. E. Isaacks, A. S. Bender, C. Y. Kim et al. // Neurochemical Research.– 1994. – Vol. 19. – P.
331–338.84.Ishimaru, H. Differentiation between high-grade glioma and metastatic braintumor using single-voxel proton MR spectroscopy / H. Ishimaru, M. Morikawa, S.Iwanaga et al. // Eur Radiol. – 2001. – Vol. 11(9). – P. 1784–1791.10585.Jemal, A.
Cancer statistics, 2010 / A. Jemal, R. Siegel, J. Xu et al. // CA: ACancer Journal for Clinicians. – 2010. – Vol. 60. – P. 277–300.86.Jessen, F. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD / F. Jessen, W.Block, F. Traber et al. // Neurology. – 2000. – Vol. 55(5). – P. 684–68887.Kallenberg, K. Untreated glioblastoma multiforme: increased myo-inositoland glutamine levels in the contralateral cerebral hemisphere at proton MRspectroscopy / K.
Kallenberg, H. C. Bock, G. Helms et al. // Radiology. - 2009. –Vol. 253. – P. 805–12.88.Kantarci, K. Regional metabolic patterns in mild cognitive impairment andAlzheimer’s disease: A 1H MRS study / K. Kantarci, C. R. Jac, Y. C. Xu et al.// Neurology. – 2000. – Vol. 55(2). – P. 210–217.89.Kantarci, K. 1H MR spectroscopy in common dementias / K. Kantarci, R.
C.Petersen, B. F. Boeve et al. // Neurology. – 2004. – Vol. 63(8). – P. 1393–1398.90.Klunk, W. E. N-acetyl-L-aspartate and other amino acid metabolites inAlzheimer’s disease brain: a preliminary proton nuclear magnetic resonance study /W. E. Klunk, K. Panchalingam, J. Moossy et al. // Neurology. – 1992. – Vol. 42(8).– P. 1578–1585.91.Komoroski, R. A. Effects of gender and region on proton MRS of normalhuman brain / R. A. Komoroski, C. Heimberg, D. Cardwell et al. // MagneticResonance Imaging. – 1999. – Vol.
17. – P. 427–433.92.Krishnan, K. R. Randomized, placebo-controlled trial of the effects ofdonepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease /K. R. Krishnan, H. C. Charles, P. M. Doraiswamy et al. // Am J Psychiatry. – 2003.– Vol. 160(11). – P. 2003–2011.93.Lai, P. H. Brain abscess and necrotic brain tumor: discrimination with protonMR spectroscopy / P. H. Lai, J. T.
Ho, W. L. Chen et al. // AJNR: American Journalof Neuroradiology. – 2002. – Vol. 23. – P. 1369–1377.10694.Langkowski, J. H. Pre-operative localized in vivo proton spectroscopy incerebral tumors at 4.0 Tesla - first results / J. H. Langkowski, J. Wieland, H.Bomsdorf et al. // Magn Reson Imaging. – 1989. – Vol. 7(5). – P. 547–555.95.Law, M. Glioma grading: sensitivity, specificity, and predictive values ofperfusion MR imaging and proton MR spectroscopic imaging compared withconventional MR imaging / M. Law, S. Yang, H.
Wang et al. // AJNR: AmericanJournal of Neuroradiology. - 2003. – Vol. 4. – P. 1989–1998.96.Law, M. High-grade gliomas and solitary metastases: differentiation by usingperfusion and proton spectroscopic MR imaging / M. Law, S. Cha, E. A. Knopp etal. // Radiology. - 2002. - Vol. 222. - P. 715–721.97.Li, B. S. Metabolite ratios to assumed stable creatine level may confound thequantification of proton brain MR spectroscopy / B.
S. Li, H. Wang, O. Gonen //Magnetic Resonance Imaging. – 2003. – Vol. 21. – P. 923–8.98.Urenjak,J.SpecificexpressionofN-acetylaspartateinneurons,oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes invitro / J. Urenjak, S. R. Williams, D. G, Gadian et al. // Journal of Neurochemistry.– 1992.
– Vol. 59. – P. 55–61.99.Lim, M. K. Systemic lupus erythematosus: brain MR imaging and single-voxel hydrogen 1 MR spectroscopy / M. K. Lim, C. H. Suh, H. J. Kim et al. //Radiology. – 2000. – Vol. 217. – P. 43–49.100. Londono, A. Unusual MR spectroscopic imaging pattern of an astrocytoma:lack of elevated choline and high myo-inositol and glycine levels / A. Londono, M.Castillo, D. Armao et al. // AJNR: American Journal of Neuroradiology.
– 2003. –Vol. 24. – P. 942–5.101. Louis D. N. The 2007 WHO classification of tumours of the central nervoussystem / D. N. Louis, H. Ohgaki, O. D. Wiestler et al. // Acta Neuropathologica. –2007. – Vol. 114. – P. 97–109.102. Hwang, J. H. Proton MR spectroscopic characteristics of pediatric pilocyticastrocytomas / J. H.
Hwang, G. F. Egnaczyk, E. Ballard et al. // AJNR: AmericanJournal of Neuroradiology. – 1998. – Vol. 19. – P. 535–40.107103. Lowry, O. H. Diversity of metabolic patterns in human brain tumors: enzymesof energy metabolism and related metabolites and cofactors / O. H. Lowry, S. J.Berger, J. G. Carter et al. // Journal of Neurochemistry. – 1983. – Vol. 41. – P.
994–1010.104. Mader, I. H MR spectroscopy of inflammation, infection and ischemia of thebrain / I. Mader, S. Rauer, P. Gall et al. // Eur J Radiol. – 2008. – Vol. 67(2). – P.250-257.105. Madhavarao, C. N. NAA synthesis and functional roles / C. N. Madhavarao,A. M. Namboodiri // New York: Springer Science + Business Media. – 2006. – Vol.60. - P. 49–66.106. Mandonnet, E. Extension of paralimbic low grade gliomas: toward ananatomical classification based on white matter invasion patterns / E. Mandonnet,L. Capelle, H. Duffau // Journal of Neuro-oncology. – 2006.
– Vol. 78. – P. 179–85.107. Mandonnet, E. Continuous growth of mean tumor diameter in a subset ofgrade II gliomas / E. Mandonnet, J. Y. Delattre, M. L. Tanguy et al. // Annals ofNeurology. – 2003. – Vol. 53. – P. 524–528.108. Martinez-Perez, I. Diagnosis of brain abscess by magnetic resonancespectroscopy / I. Martinez-Perez, A. Moreno, J. Alonso et al.
// J Neurosurg. - 1997.– Vol. 86. – P. 708-713.109. McKnight, T. R. Correlation of magnetic resonance spectroscopic and growthcharacteristics within Grades II and III gliomas / T. R. McKnight, K. R. Lamborn,T. D. Love et al. // Journal of Neurosurgery. – 2007. – Vol. 106. – P. 660–666.110. Meyerhoff, D. J. Axonal injury and membrane alterations in Alzheimer’sdisease suggested by in vivo proton magnetic resonance spectroscopic imaging / D.J. Meyerhoff, S.
MacKay, J. M. Constans et al. // Ann Neurol. – 1994. – Vol. 36(1).– P. 40–47.111.Miller, D.H. Nuclear magnetic resonance monitoring of treatment andprediction of outcome in multiple sclerosis / D. H. Miller, A. J. Thompson // Biol.Sci. – 1999. – Vol. 354(1390). – P. 1687-1695.108112. Moats, R. A. Abnormal cerebral metabolite concentrations in patients withprobable Alzheimer disease / R. A. Moats, T. Ernst, T. K. Shonk // Magn ResonMed. – 1994. – Vol. 32(1).
– P. 110–115.113. Moffett, J. R. N-acetylaspartate in the CNS: from neurodiagnostics toneurobiology / J. R. Moffett, B. Ross, P. Arun et al. // Progress in Neurobiology. –2007. – Vol. 81. – P. 89–131.114. Mohanakrishnan, P. Regional Metabolic Alterations in Alzheimer's Disease:An in vitro 1H NMR Study of the Hippocampus and Cerebellum / P.Mohanakrishnan, A.
Fowler, J. Paul et al. // The Journals of Gerontology Series A:Biological Sciences and Medical Sciences. – 1997. – Vol. 52A(2). – P. 111-117.115. Moller-Hartmann, W. Clinical application of proton magnetic resonancespectroscopy in the diagnosis of intracranial mass lesions / W. Moller-Hartmann, S.Herminghaus, T. Krings et al. // Neuroradiology. – 2002. – Vol. 44. – P. 371–81.116. Moller-Hartmann, W. L-aspartic acid formation prom N-acetyl-aspartic acidin the brain / W. Moller-Hartmann, S. Herminghaus, T. Krings et al. // PsychiatryClin Neurosci.
– 1961. – Vol. 15(1). – P. 4-9.117. Neale, J. H. N-acetylaspartylglutamate: the most abundant peptideneurotransmitter in the mammalian central nervous system / J. H. Neale, T. T.Bzdega, B. Wroblewska // Journal of Neurochemistry. – 2000. – Vol. 75. – P. 443–452.118. Oliver, L. Hypoxia and the malignant glioma microenvironment: regulationand implications for therapy / L. Oliver, C. Olivier, F. B. Marhuenda // CurrentMolecular Pharmacology. – 2009. – Vol. 2.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
